Irinotecan
- Product Name
- Irinotecan
- CAS No.
- 97682-44-5
- Chemical Name
- Irinotecan
- Synonyms
- CPT-11;IRINOTECAN HCL;CAMPTOSAR;Irinotecan(TECANS);Irinotecan (free Base);[1,4'-BIPIPERIDINE]-1'-CARBOXYLIC ACID;(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11}.0^{4,9}.0^{15,20}]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl 4-(piperidin-1-yl)piperidine-1-carboxylate;DQ-2805;SN-38-11;IRINOTECAN
- CBNumber
- CB1124156
- Molecular Formula
- C33H38N4O6
- Formula Weight
- 586.68
- MOL File
- 97682-44-5.mol
Irinotecan Property
- Melting point:
- 222-223°
- Boiling point:
- 873.4±65.0 °C(Predicted)
- Density
- 1.40±0.1 g/cm3(Predicted)
- storage temp.
- Sealed in dry,2-8°C
- solubility
- Acetonitrile (Slightly, Heated, Sonicated), DMSO (Slightly), Methanol (Slightly)
- pka
- 11.20±0.20(Predicted)
- form
- Solid
- color
- White to Brown
- CAS DataBase Reference
- 97682-44-5(CAS DataBase Reference)
Safety
- Hazard Codes
- Xn
- Risk Statements
- 22
- RTECS
- DW1061000
- Hazardous Substances Data
- 97682-44-5(Hazardous Substances Data)
Hazard and Precautionary Statements (GHS)
- Symbol(GHS)
-
- Signal word
- Danger
- Hazard statements
-
H302Harmful if swallowed
H315Causes skin irritation
H318Causes serious eye damage
H361Suspected of damaging fertility or the unborn child
H373May cause damage to organs through prolonged or repeated exposure
- Precautionary statements
-
P201Obtain special instructions before use.
P202Do not handle until all safety precautions have been read and understood.
P260Do not breathe dust/fume/gas/mist/vapours/spray.
P264Wash hands thoroughly after handling.
P264Wash skin thouroughly after handling.
P270Do not eat, drink or smoke when using this product.
P280Wear protective gloves/protective clothing/eye protection/face protection.
P281Use personal protective equipment as required.
P301+P312IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P302+P352IF ON SKIN: wash with plenty of soap and water.
P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.
P308+P313IF exposed or concerned: Get medical advice/attention.
P310Immediately call a POISON CENTER or doctor/physician.
P314Get medical advice/attention if you feel unwell.
P321Specific treatment (see … on this label).
P330Rinse mouth.
P332+P313IF SKIN irritation occurs: Get medical advice/attention.
P362Take off contaminated clothing and wash before reuse.
P405Store locked up.
P501Dispose of contents/container to..…
N-Bromosuccinimide Price
- Product number
- 2688
- Product name
- CPT11
- Purity
- ≥99%(HPLC)
- Packaging
- 10
- Price
- $229
- Updated
- 2021/12/16
- Product number
- 2688
- Product name
- CPT11
- Purity
- ≥99%(HPLC)
- Packaging
- 50
- Price
- $960
- Updated
- 2021/12/16
- Product number
- 255047
- Product name
- CPT 11
- Packaging
- 10mg
- Price
- $480
- Updated
- 2021/12/16
- Product number
- I767523
- Product name
- (+)-Irinotecan
- Packaging
- 50mg
- Price
- $60
- Updated
- 2021/12/16
- Product number
- FI33814
- Product name
- Irinotecan
- Packaging
- 100mg
- Price
- $60
- Updated
- 2021/12/16
Irinotecan Chemical Properties,Usage,Production
Uses
(+)-Irinotecan is a Topo I inhibitor.
Uses
Irinotecan is a topoisomerase I inhibitor for LoVo cells and HT-29 cells with IC50 of 15.8 μM and 5.17 μM, respectively
Definition
ChEBI: A member of the class of pyranoindolizinoquinolines that is the carbamate ester obtained by formal condensation of the carboxy group of [1,4'-bipiperidine]-1'-carboxylic acid with the phenolic hydroxy group of (4S)-4,11-diethyl-4,9-dihydro y-1H-pyrano[3',4':6,7]indolizino[1,2- hydrochloride]quinoline-3,14-dione. Used (in the form of its hydrochloride salt trihydrate) in combination with fluorouracil and leucovorin, for the treatment of patients with metastatic adenocarcino a of the pancreas after disease progression following gemcitabine-based therapy. It is converted via hydrolysis of the carbamate linkage to its active metabolite, SN-38, which is ~1000 times more active.
brand name
Camptosar (Pharmacia &Upjohn) .
Biological Activity
irinotecan (cpt-11), a prodrug for treating metastatic colorectal cancer, is a topoisomerase i inhibitor for lovo cells and ht-29 cells with ic50 of 15.8 μm and 5.17 μm, respectively [1].in vivo, irinotecan is converted to sn-38, its most active metabolite, by carboxylesterase converting enzyme (cce) [2].
in vitro
irinotecan induced similar amounts of cleavable complexes in lovocells and ht-29 cell lines with the ic50 of 15.8 μm and 5.17 μm, respectively [1].after addition of 157 mm irinotecan to plasma, sn-38 concentration showed linear increase during the first 60-min period, followed by a plateau.in the first 60 min, mean and standard deviation of the conversion rate were 515.9 ± 50.1 pmol/ml/h (n = 69), with a coefficient of variation of 0.097 [2]. irinotecan (cpt-11) was significantly more active in sclc than in nsclccelllines (p = 0.0036). ce activity appeared to be associated with higher sensitivity to cpt-11 in human lung cancercelllines and may partly explain the difference in the in vitro sensitivity to cpt-11 between sclc and nsclccells [3].in vitro, the sensitivity to cpt-11 and sn-38 was highest in ls174t and colo 320cells, intermediate in sw1398cellsand lowest in colo 205 and widr cells. the activity of sn-38 was 130 to 570 times than cpt-11[4].
in vivo
in colo 320 xenografts, irinotecan induced a maximum growth inhibition of 92% [4].a single dose of irinotecan significantly increased amounts of topoisomerase i covalently bound to dna in stomach, duodenum, colon and liver. concomitantly, the irinotecan-treated group exihibited significantly higher amounts of dna strand breaks in colon mucosa cells compared to the control group [5].
References
[1]. tobin p, clarke s, seale j p, et al. the in vitro metabolism of irinotecan (cpt‐11) by carboxylesterase and β‐glucuronidase in human colorectal tumours[j]. british journal of clinical pharmacology, 2006, 62(1): 122-129.
[2]. shingyoji m, takiguchi y, watanabe‐uruma r, et al. in vitro conversion of irinotecan to sn‐38 in human plasma[j]. cancer science, 2004, 95(6): 537-540.
[3]. van ark-otte j, kedde m a, van der vijgh w j, et al. determinants of cpt-11 and sn-38 activities in human lung cancer cells[j]. british journal of cancer, 1998, 77(12): 2171.
[4]. jansen w j m, zwart b, hulscher s t m, et al. cpt-11 in human colon-cancer cell lines and xenografts: characterization of cellular sensitivity determinants[j]. international journal of cancer, 1997, 70(3): 335-340.
[5]. na y s, jung k a, kim s m, et al. the histone deacetylase inhibitor pxd101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models[j]. cancer chemotherapy and pharmacology, 2011, 68(2): 389-398.
Irinotecan Preparation Products And Raw materials
Raw materials
Preparation Products
Irinotecan Suppliers
- Tel
- --
- Fax
- --
- Country
- Switzerland
- ProdList
- 6896
- Advantage
- 91
View Lastest Price from Irinotecan manufacturers
- Product
- Irinotecan 97682-44-5
- Price
- US $825.00/g/Bag
- Min. Order
- 10g
- Purity
- 99%
- Supply Ability
- 1kg
- Release date
- 2021-06-03
- Product
- lrinotecan 97682-44-5
- Price
- US $0.00/kg
- Min. Order
- 1kg
- Purity
- 99%
- Supply Ability
- 2000ton
- Release date
- 2023-09-07
- Product
- Irinotecan 97682-44-5
- Price
- US $0.00-0.00/kg
- Min. Order
- 1kg
- Purity
- 99.9%
- Supply Ability
- 20 tons
- Release date
- 2023-06-26